Suppr超能文献

α-2b干扰素治疗毛细胞白血病时的外周和脾内血小板动力学及骨髓巨核细胞生成

Peripheral and intrasplenic platelet kinetics and bone marrow megakaryopoiesis in alpha-2b-interferon treated hairy cell leukemia.

作者信息

Wadenvik H, Braide I, Ridell B, Kutti J, Jacobsson S, Revesz P

机构信息

Department of Medicine, Sahlgren's Hospital, University of Göteborg, Sweden.

出版信息

Leuk Res. 1994 Aug;18(8):569-75. doi: 10.1016/0145-2126(94)90038-8.

Abstract

In eight patients with previously untreated hairy cell leukemia (HCL), by using 111In-labelled platelets and megakaryocyte quantitation, the splenic platelet pooling and the platelet production rate (P) were evaluated before and during alpha-2b-interferon (IFN) treatment. Both before and after 8 months of IFN therapy the spleen was shown to pool a sizeable amount of the total body platelet mass. The average splenic platelet pools, prior to and after 8 months of IFN, were 58 +/- 17 and 47 +/- 11%, respectively. At the time when treatment was initiated, the patients were heterogeneous as regards the spleen size, platelet kinetics, and the bone marrow morphology. Three patients had values for P below the 95th percentile for a group of healthy control subjects; following IFN therapy they displayed a substantial increase in P. In three other HCL patients, with the largest spleens, the pre-treatment P was normal, or slightly above the values seen for the control subjects. In these patients, changes in splenic platelet pool size, blood volume, and platelet mean life-span accounted for the increase in platelet count observed in response to IFN. The mean megakaryocyte number and volume per microliter bone marrow increased during IFN therapy, while the mean P remained slightly reduced. It is concluded that splenic platelet pooling would explain the previously described difference in platelet counts between splenectomized and non-splenectomized patients treated with IFN.

摘要

在8例未经治疗的毛细胞白血病(HCL)患者中,通过使用铟-111标记的血小板和巨核细胞定量,在α-2b干扰素(IFN)治疗前及治疗期间评估了脾脏血小板池和血小板生成率(P)。在IFN治疗8个月前后,脾脏均显示可蓄积相当数量的全身血小板总量。IFN治疗8个月前后,平均脾脏血小板池分别为58±17%和47±11%。开始治疗时,患者在脾脏大小、血小板动力学和骨髓形态方面存在异质性。3例患者的P值低于一组健康对照者的第95百分位数;IFN治疗后,他们的P值显著增加。在另外3例脾脏最大的HCL患者中,治疗前的P值正常,或略高于对照者的值。在这些患者中,脾脏血小板池大小、血容量和血小板平均寿命的变化解释了IFN治疗后观察到的血小板计数增加。IFN治疗期间,每微升骨髓中的平均巨核细胞数量和体积增加,而平均P值仍略有降低。结论是,脾脏血小板池可以解释先前描述的接受IFN治疗的脾切除和未脾切除患者之间血小板计数的差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验